Reuters: Bankruptcy News: K-V Pharmaceutical files for bankruptcy protection

Reuters: Bankruptcy News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

K-V Pharmaceutical files for bankruptcy protection Aug 4th 2012, 19:30 CHICAGO | Sat Aug 4, 2012 3:30pm EDT CHICAGO Aug 4 (Reuters) - K-V Pharmaceutical, a Bridgeton-Missouri based company focused on women's healthcare products, filed for bankruptcy protection on Saturday, blaming federal actions that kept it from getting "full value" of a drug aimed at preventing premature births. The company, founded in 1942, listed debts of $728.3 million and assets of $236.6 million in a filing in bankruptcy court in New York. The company blamed the bankruptcy on its "inability to realize the full value of Makena," the drug to help avoid premature births, because of the Food and Drug Administration's refusal to enforce orphan drug marketing exclusivity for it, Thomas McHugh, the company's treasurer and vice president, said in declaration filed with the court. The company also said it was hurt by restrictions on reimbursements imposed by state Medicaid agencies. McHugh also blamed restrictions on manufacturing and marketing of its other products that were imposed as a part of a 2009 consent decree with the Justice Department after a recall of products, including some tablets that may have been oversized. In 2010, KV's Ethex unit pled guilty to failing to alert drug authorities about pill manufacturing problems, and agreed to pay a criminal fine of $23.4 million. The following year, former CEO Mark Hermelin pled guilty to violating drug labeling laws. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions